Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNephrologyNeighborhood Health Plan RI Empaveli Coverage | Op…
    Ask Trek AI about this page
    CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

    Empaveli (pegcetacoplan) — Non-Oncology Coverage Criteria (Subcutaneous)

    Customize your policy alerts

    Sign up for all Neighborhood Health Plan of Rhode Island policy alerts

    Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and coverage criteria for Empaveli (pegcetacoplan) subcutaneous use to reduce proteinuria in members (≥12 years) with C3G or IC-MPGN; applies to Medicaid, Commercial, and Medicare lines of business.

    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyEmpaveli (pegcetacoplan) — Non-Oncology Coverage Criteria (Subcutaneous)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 1, 2026
    Last ReviewFeb 10, 2026
    Next Review DateFeb 10, 2026
    Key ActionObtain prior authorization; initial approvals valid for 6 months and may be renewed every 6 months when renewal criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 moInitial PA duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1,080 mg x2/wkAdult maintenance dose
    ≥30Min eGFR
    UPCR ≥1 g/gProteinuria threshold
    2,160 mgMax units (7d)

    Coverage Criteria for Empaveli (pegcetacoplan)

    Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Initial Approval Criteria: 1) Diagnosis: C3G confirmed by kidney biopsy OR IC-MPGN confirmed by kidney biopsy; 2) Age: member is 12 years of age or older; 3) Prescriber: drug is being prescribed by or in consultation with a nephrologist; 4) Proteinuria: urine protein-to-creatinine ratio (UPCR) >= 1 g/g OR proteinuria >= 1.0 g/day; 5) Kidney function: eGFR >= 30 mL/min/1.73 m2; 6) Concomitant therapy: member is receiving a stable dose of maximally tolerated renin-angiotensin system (RAS) inhibitor therapy (ACEI or ARB) for at least 3 months prior to initiation and will continue on that dose with the requested drug, OR has an intolerance or contraindication to RAS inhibitors; 7) Concomitant use: member will NOT be using the requested agent in combination with Fabhalta (iptacopan); 8) Safety: member does NOT have any FDA-labeled contraindications to the requested agent; 9) Dosing: requested dosing is consistent with recommended regimen (typical adult dose 1,080 mg subcutaneously twice weekly).

    All conditions required for initial coverage.

    Continuation/Renewal Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Renewal Criteria: 1) Diagnosis: C3G or IC-MPGN; 2) Prescriber: drug is being prescribed by or in consultation with a nephrologist; 3) Clinical response: member has had improvements or stabilization as indicated by EITHER a decrease from baseline in UPCR OR a decrease from baseline in proteinuria; 4) Continued RAS inhibitor therapy at a stable, maximally tolerated dose, or documented intolerance/contraindication to RAS inhibitors; 5) Kidney function: documentation that eGFR remains >= 30 mL/min/1.73 m2; 6) Concomitant use: member will NOT be using the requested agent in combination with Fabhalta (iptacopan); 7) Safety: member does NOT have any FDA-labeled contraindications to the requested agent.
    Authorization Duration: Initial and renewal authorizations valid for 6 months; renewals may be granted every 6 months when criteria are met.

    Use of Empaveli (pegcetacoplan) in combination with Fabhalta (iptacopan) is not permitted. In addition, members with any FDA‑labeled contraindications to Empaveli are excluded from coverage decisions and should not be approved for therapy.

    Requests that do not meet all initial or renewal criteria may be considered not medically necessary and may be denied. Examples include absence of kidney biopsy confirmation of C3G or IC‑MPGN, proteinuria below the initiation threshold of UPCR < 1 g/g (or < 1.0 g/day), or eGFR < 30 mL/min/1.73 m2. Other grounds for exclusion include lack of nephrologist involvement, failure to document stable, maximally tolerated RAS inhibitor therapy (or documented intolerance), concomitant use with iptacopan, or any FDA‑labeled contraindication.

    Coding and Clinical Thresholds

    HCPCS codesHCPCS
    J7799Non-covered drugs, other than inhalation drugs, administered through DME (as listed)
    C9399Unclassified drugs or biologicals (Hospital Outpatient Use Only)
    J3490Unclassified drugs
    HCPCS codes (short list)HCPCS
    No codes listed
    NDCNDC
    73606-0010-xxEmpaveli 1,080 mg/20 mL solution in single-dose vials for subcutaneous infusion
    Covered Diagnosis CodesICD-10Covered
    D59.5Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]
    N00.AAcute nephritic syndrome with C3 glomerulonephritis
    N00.5Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis
    N00.6Acute nephritic syndrome with dense deposit disease
    N01.ARapidly progressive nephritic syndrome with C3 glomerulonephritis
    N01.5Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis
    N01.6Rapidly progressive nephritic syndrome with dense deposit disease
    N02.ARecurrent and persistent hematuria with C3 glomerulonephritis
    N02.5Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis
    N02.6Recurrent and persistent hematuria with dense deposit disease
    1–10 of 25
    1/3
    inv-08: eGFR — numeric threshold for initiation/renewal
    Minimum eGFR for initiation>= 30 mL/min/1.73 m2
    eGFR requirement for renewalDocumentation that member's eGFR remains >= 30 mL/min/1.73 m2
    Measurement basiseGFR reported in mL/min/1.73 m2 as recorded in medical records
    inv-09: UPCR / proteinuria — numeric threshold used for initiation and monitoring
    Initiation threshold (UPCR)>= 1 g/g (urine protein-to-creatinine ratio)
    Alternative initiation metric>= 1.0 g/day proteinuria

    Provider Actions, Authorization, and Documentation

    Prior Authorization

    Prior authorization required; 6‑month approvals

    Prior authorization is required for Empaveli; initial authorizations are valid for 6 months and may be renewed every 6 months when renewal criteria are met.

    • HCPCS codes to bill: J7799, C9399, J3490.
    Step Therapy

    Step therapy exception for recent Medicare use (365 days)

    Medicare members who received Empaveli within the prior 365 days are exempt from the plan's step therapy requirements and do not need to meet step therapy prior to approval.

    Documentation Required

    Background on Empaveli (pegcetacoplan)

    Empaveli (pegcetacoplan) is a targeted C3 complement inhibitor indicated to reduce proteinuria in patients with biopsy‑confirmed C3 glomerulopathy (C3G) or immune‑complex membranoproliferative glomerulonephritis (IC‑MPGN). The agent is approved for use in adults and pediatric patients aged 12 years and older and demonstrated reductions in UPCR and improvement in renal outcomes in clinical trials.

    Definitions and Abbreviations

    inv-15: C3G / IC-MPGN — Definition and requirement for biopsy confirmation
    DefinitionComplement 3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) — biopsy-confirmed complement-mediated glomerular diseases associated with proteinuria.
    Biopsy requirementDiagnosis must be confirmed by kidney biopsy (C3G confirmed by kidney biopsy OR IC-MPGN confirmed by kidney biopsy) for initial coverage.
    Evidence basisClinical evidence supporting use includes a randomized trial (Study APL2-C3G-310) enrolling members with biopsy-proven disease demonstrating significant UPCR reductions.
    inv-16: UPCR — Urine protein-to-creatinine ratio threshold used for coverage decisions and response monitoring
    Coverage threshold (initiation)>= 1 g/g UPCR
    Alternative coverage threshold
    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyEmpaveli (pegcetacoplan) — Non-Oncology Coverage Criteria (Subcutaneous)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 1, 2026
    Last ReviewFeb 10, 2026
    Next Review DateFeb 10, 2026
    Key ActionObtain prior authorization; initial approvals valid for 6 months and may be renewed every 6 months when renewal criteria are met.
    SourceLink
    On This Page
    Coverage Criteria for Empaveli (pegcetacoplan)Coding and Clinical ThresholdsProvider Actions, Authorization, and DocumentationBackground on Empaveli (pegcetacoplan)Definitions and Abbreviations
    Renewal/response monitoringRenewal requires decrease from baseline in UPCR or decrease from baseline in proteinuria

    Required clinical documentation to support authorization

    Submit documentation confirming diagnosis and monitoring: a kidney biopsy confirming C3G or IC‑MPGN, baseline and follow‑up UPCR and eGFR values, and evidence that the drug is prescribed by or in consultation with a nephrologist; include documentation of current RAS inhibitor therapy or documented intolerance/contraindication.

    • Kidney biopsy report confirming C3G or IC‑MPGN.
    • Baseline UPCR and serial UPCR or proteinuria measurements showing response for renewals.
    • Baseline and follow‑up eGFR demonstrating ≥30 mL/min/1.73 m2 for initiation and maintenance.
    • Nephrologist prescription or consultation note and documentation of stable maximally tolerated ACEI/ARB therapy or documented intolerance.
    Denial Risk

    Triggers for denial if criteria not met

    Requests may be denied if the coverage criteria are not met — for example, no biopsy confirmation of C3G/IC‑MPGN, member age under 12 years, UPCR below 1 g/g (or proteinuria <1.0 g/day), eGFR <30 mL/min/1.73 m2, lack of nephrologist involvement, absence of adequate RAS inhibitor therapy without documented intolerance, or concomitant use with Fabhalta (iptacopan).

    • Diagnosis must be biopsy‑confirmed C3G or IC‑MPGN.
    • Member must be ≥12 years of age.
    • UPCR must be ≥1 g/g (or proteinuria ≥1.0 g/day) for initiation.
    • eGFR must be ≥30 mL/min/1.73 m2 for initiation and renewal.
    • Concomitant use with Fabhalta (iptacopan) will preclude approval.
    • Lack of nephrologist prescribing/consultation or no evidence of adequate RAS inhibitor therapy (unless intolerance documented) may result in denial.
    >= 1.0 g/day proteinuria
    Response monitoring for renewalDocumentation of decrease from baseline in UPCR OR decrease from baseline in proteinuria is required to demonstrate improvement or stabilization for renewal.